OHDSI MEETINGS THIS WEEK
OHDSI Community Call - Tuesday at 12pm EThttps://meetings.webex.com/collabs/#/meetings/detail?uuid=M59X2V1U61WC9ASID2Z5N3UT95-D1JL&rnd=811649.986822111
CDM and Vocabulary WG - Tuesday at 1pm EThttps://jjconferencing.webex.com/mw3100/mywebex/default.do?service=1&main_url=%2Fmc3100%2Fe.do%3Fsiteurl%3Djjconferencing%26AT%3DMI%26EventID%3D594628767%26MTID%3Dma32e5ce14c744149f041412fc99040f1%26Host%3DQUhTSwAAAASVgMyDOQd7vb9BN5k-UptJa_Gk1J-zE2cQn8vAktuQMo0Xmp8zuA_NCNpDQIiZrtOZRGYiH4-uB_6yxaZ4Slqe0%26FrameSet%3D2&siteurl=jjconferencing&nomenu=true
Population-Level Estimation (Eastern hemisphere) workgroup meeting - Wednesday at 3pm Hong Kong timehttps://meetings.webex.com/collabs/meetings/join?uuid=M6WE9AOKFETH2VEFPVCZWWBIT0-D1JL
Architecture Working Group - Thursday at 10am EThttps://jjconferencing.webex.com/jjconferencing/j.php?MTID=m3e1ceeca56f1e94c9fcf1ae98c10e02e
GIS working group meeting - Next Monday (April 9th) at 10am ET
Simple, modern video meetings for the global workforce. Join from anywhere, including your desktop, browser, mobile device, or video room device.
ANNOUNCEMENTS
2018 OHDSI F2F: Selected F2F participants were notified on Friday, March, 23rd. If you signed up to attend but did not receive confirmation of your attendance place email beaton@ohdsi.org
2018 OHDSI Symposium - Collaborator showcase
Instant gratification is not soon enough.
COMMUNITY PUBLICATIONS
Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009-2014.
I Marcianò, Y Ingrasciotta, F Giorgianni, V Ientile, A Chinellato, DU Tari, R Gini, S Cannavò, M Pastorello, S Scondotto, P Cananzi, G Traversa, F Trotta, V Belleudi, A Addis and G Trifirò,
Frontiers in endocrinology , 2018
Somatropin [recombinant growth hormone (rGH)] is approved in children and adults for several conditions involving growth disturbances and the corresponding biosimilar is available in Italy since 2006. No population-based data are available on the pattern of rGH use in Italian clinical practice. This study aimed at exploring the pattern of biosimilar and originator rGH use in six Italian centers, where different policy interventions promoted biosimilar use.This population-based, drug-utilization study was conducted in the years 2009-2014, using administrative databases of Umbria, Tuscany, and Lazio Regions and Local Health Units of Caserta, Treviso, and Palermo. Naïve rGH users were characterized, and prevalence of use and discontinuation were assessed over time.Among 6,785 patients treated with rGH during the study years, 4,493 (66.2%) were naïve users (males/females = 1.3), mostly affected by GH deficiency. The prevalence of rGH use increased from 2009 to 2010, remaining stable thereafter, but it was heterogeneous across centers (twofold higher prevalence of use in center n.2 than centers n.4 and 1 in 2014). Biosimilar rGH uptake increased over time but was low (7.8% in 2014) and heterogeneous as well. Discontinuation of rGH therapy occurred in 54.0% of naïve users, more frequently in females than males (58.1 vs. 50.9%). During the first year of treatment, discontinuation was frequent (39.9%), but no statistically significant differences were observed in treatment persistence for biosimilar vs. originator rGH (p > 0.05).Geographical heterogeneity in the prevalence of rGH use was observed. Similarly, the biosimilar rGH uptake was low and variable across centers. Post-marketing monitoring is required to continuously monitor the benefit-risk profile of rGH, thus guaranteeing greater savings than only promoting lowest cost rGH.
Real world use of biological drugs in patients with psoriasis/psoriatic arthritis: a retrospective, population-based study from Southern Italy in the years 2010-2014.
I Marcianò, MP Randazzo, P Panagia, R Intelisano, C Sgroi, V Ientile, S Cannavò, C Guarneri, P Reitano, E Spina and G Trifirò,
Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia , Mar 26 2018
Biological drugs, such as infliximab, etanercept, adalimumab, ustekinumab, golimumab and certolizumab are third-line therapy for psoriasis (PsO) and psoriatic arthritis (PsA), but they may be used at earlier stage in severe forms. This study investigated the pattern of use and costs of biological drugs for PsO/PsA in a large population from Southern Italy during the years 2010-2014.This was a retrospective, population-based, drug-utilization study, using healthcare administrative databases of the Local Health Unit and two hospitals of Messina Province (Sicily) in the years 2010-2014. Incident users of adalimumab, ustekinumab, infliximab, etanercept and golimumab for PsO/PsA were characterized. Yearly prevalence of use and costs, as well as time to treatment discontinuation and switch were assessed.During the study period, 517 patients received at least one study drugs prescription for PsO/PsA and 304 (58.8%) were incident users, mostly treated with adalimumab (33.6%). Incident users were mostly males (59.8%), with a median age of 49 years. Prevalence of biological drugs users in PsO/PsA increased from 4.3 to 6.9 per 10,000 inhabitants from 2011 to 2014. Pharmaceutical expenditure of the study drugs almost doubled (from 2.6 to 4.7 million euros during 5 observation years). During the first year of treatment, discontinuation occurred in 31.8% of incident users and switch was not infrequent (7.4%).Prevalence of use and costs of biological drugs for PsO/PsA substantially increased in recent years in a large population of Southern Italy. Larger uptake of lowest cost biological drugs, and biosimilars whenever available, may help access to the most innovative drugs.
